Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion
Statistics in Medicine · 2026
DOI: 10.1002/sim.70733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von Masahiro Kojima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chuo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Maximum Tolerated Dose, Models, Statistical, Clinical Trials, Phase I as Topic, Research Design. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
In oncology phase I trials, model‐assisted designs have been increasingly adopted because they enable adaptive yet operationally simple dose adjustment based on accumulating safety data, leading to a paradigm shift in dose‐escalation methodology. In practice, a single mid‐trial dose insertion may be considered to examine safer doses and/or to collect more informative efficacy data. In this study, we investigate methods to improve dose assignment and the selection of the maximum tolerated dose (MTD) or the optimal biological dose (OBD) when a new dose level is added during an ongoing trial under a model‐assisted framework, by assigning informative prior information to the inserted dose. We propose a hybrid design that uses a non‐informative model‐assisted design at trial initiation and, upon dose insertion, applies an informative‐prior extension only to the newly added dose. In addition, to address potential skeleton misspecification, we propose two adaptive extensions: (i) an online‐weighting approach that updates the skeleton over time, and (ii) a Bayesian‐mixture approach that robustly combines multiple candidate skeletons. We evaluate the proposed methods through simulation studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chuo University, Tokyo, Japan.
- The Institute of Statistical Mathematics, Tokyo, Japan.
- Institute of Science Tokyo, Tokyo, Japan.
- The University of Osaka, Osaka, Japan.
- Astellas Pharma Global Development Inc., Tokyo, Japan.
- Wakayama Medical University, Wakayama, Japan.
ORCID-Profile: Masahiro Kojima
Förderung
- JSPS KAKENHI
Zitieren
APA
Kojima, M., Yamada, K., Sunami, H., Takeda, K., & Hanada, K. (2026). Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion. Statistics in Medicine. https://doi.org/10.1002/sim.70733
Vancouver
Kojima M, Yamada K, Sunami H, Takeda K, Hanada K. Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion. Statistics in Medicine. 2026. doi:10.1002/sim.70733
BibTeX
@article{Kojima2026,
author = {Kojima, Masahiro and Yamada, Kana and Sunami, Hisato and Takeda, Kentaro and Hanada, Keisuke},
title = {Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion},
journal = {Statistics in Medicine},
year = {2026},
doi = {10.1002/sim.70733}
}
EUVIMED